Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease
Open Access
- 30 April 2019
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 37 (6) , 444-450
Abstract
Background: Adalimumab (ADA) is an anti-tumor necrosis factor agent that has been shown to be effective in inducing and maintaining remission in adult patients with inflammatory bowel disease. The relationship between the ADA trough levels and clinical efficacy has been demonstrated, but there is variability in the definition of the most suitable range for its clinical applicability. Summary: A review of published studies during the last 5 years on ADA serum levels and its relationship with the clinical outcome was performed. The studies selected included 7 observational studies, a systematic review, a meta-analysis and a post hoc analysis of a clinical trial. The reported ADA levels that discriminate patients in clinical remission from those with active disease range from 4.5 to 8 µg/mL. This therapeutic range varies when considering endoscopic remission (7.5 to >13.9 µg/mL). Although the sample of patients with ulcerative colitis is small, a tendency to reach higher levels of ADA is observed in both clinical and endoscopic remission. Key Messages: The optimal therapeutic cut-off point of serum ADA levels ranges from 4.5–5 to 12 µg/mL, where ADA levels are associated with an adequate clinical monitoring of the disease during maintenance therapy. These ranges vary according to the target, suggesting levels of 4.8 µg/mL as the cut-off for clinical remission and levels ≥7.5 µg/mL for mucosal healing/endoscopic response. Controlled prospective studies are required to determine the optimal therapeutic interval of ADA serum levels both as induction and as maintenance therapy.Keywords
This publication has 19 references indexed in Scilit:
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel DiseaseGastroenterology, 2017
- American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel DiseasesGastroenterology, 2017
- Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel diseaseExpert Opinion on Drug Safety, 2016
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2016
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or AdalimumabClinical Gastroenterology and Hepatology, 2015
- Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumabDigestive and Liver Disease, 2014
- Pharmacokinetics of Biologics and the Role of Therapeutic MonitoringGastroenterology Clinics of North America, 2014
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s diseaseJournal of Gastroenterology, 2013
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006